

Merck joins TRANSVAC2 programme to advance vaccine development

21 May 2019 | News

TRANSVAC2, part of the EU's Horizon 2020 program, provides trainings to streamline vaccine manufacturing and development



Merck, a leading science and technology company, has announced its participation in a collaboration with the Vaccine Formulation Institute and the European Vaccine Initiative. The effort will provide vaccine process development training courses within TRANSVAC2, a collaborative infrastructure project under Horizon 2020.

Funded by the European Commission (EC), TRANSVAC2 exists in part to accelerate vaccine development by enhancing European vaccine research and training and increase sustainability of EC vaccine projects by implementing a permanent research infrastructure for early vaccine development. Merck is among a list of collaborators joining the TRANSVAC2 program.

As part of the program, Merck will hold a two-day training module in 2019 and in 2021 and will host applicants, selected by the TRANSVAC2 Course Selection Panel, at Merck's recently inaugurated M Lab™ Collaboration Center in Molsheim, France. Participants will experience simulated lab processes, which will help them acquire fundamental skills needed for process development and will acquaint them with a single-use environment.